Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








The Janssen COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events						Print
																Related Pages
										Local Reactions
Local reactions were reported at higher rates by vaccine recipients than placebo recipients. The frequency of any local reaction was higher in participants aged 18 to 59 years than participants aged ≥60 years (59.8% vs 35.4%). Pain at the injection site was the most frequently reported solicited local reaction among vaccine recipients (58.6% of 18-59-year-olds and 33.3% ≥60-year-olds). Erythema and swelling were reported less frequently. No grade 4 local reactions were reported. Overall, the median onset of local reactions in the vaccine group was within two days of vaccination, with a median duration 2 days for erythema and pain and 3 days for swelling. (Table 1)Table 1. Local reactions in persons aged 18-59 years and persons aged ≥60 years, Janssen COVID-19 vaccine and placeboa
Table 1. Local reactions in persons aged 18-59 years and persons aged ≥60 years, Janssen COVID-19 vaccine and placebo
**18-59 years**
**≥60 years****Janssen Vaccine
N=2036**
Placebo
N=**2049**
**Janssen**Vaccine
N=1320
Placebo
N=1331**Any Local, n (%)**Any
1218 (59.8)
413 (20.2)
467 (35.4)
244 (18.3)Grade 3
18 (0.9)
4 (0.2)
5 (0.4)
2 (0.2)**Painb, n (%)**Any
1193 (58.6)
357 (17.4)
439 (33.3)
207 (15.6)Grade 3
8 (0.4)
0 (0.0)
3 (0.2)
2 (0.2)**Erythemac, n (%)**Any
184 (9.0)
89 (4.3)
61 (4.6)
42 (3.2)Grade 3
6 (0.3)
2 (0.1)
1 (0.1)
0 (0.0)**Swellingc, n (%)**Any
142 (7.0)
32 (1.6)
36 (2.7)
21 (1.6)Grade 3
5 (0.2)
2 (0.1)
2 (0.2)
0 (0.0)
aSolicited local and systemic adverse reactions collected for participants in a safety subset (N=6,736)
bPain – Grade 3: any use of prescription pain reliever or prevented daily activity
cErythema and Swelling – Grade 3: >100mm
Note: No grade 4 local reactions were reported.Systemic Reactions
Systemic reactions were reported at higher rates by vaccine recipients than placebo recipients. The frequency of systemic reactions was higher in participants aged 18-59 years than participants ≥60 years (61.5% vs 45.3%). For both age groups, fatigue and headache were the most commonly reported systemic reactions. Fever was more common in participants 18-59 years (12.8%) compared to those ≥60 years (3.1%). The majority of systemic reactions were mild or moderate in severity. The most common grade 3 reactions were fatigue and myalgia. No grade 4 reactions were reported. Among vaccine recipients, the median onset of systemic reactions within 2 days of vaccination, with a median duration of 1-2 days. (Table 2)Table 2. Systemic reactions in persons aged 18-59 years and persons aged ≥60 years, Janssen COVID-19 vaccine and placeboa
Table 2. Systemic reactions in persons aged 18-59 years and persons aged ≥60 years, Janssen COVID-19 vaccine and placebo
**18-59 years**
**≥60 years****Janssen Vaccine
N=2036**
**Placebo
N=2049**
**Janssen Vaccine
N=1320**
**Placebo
N=1331****Any systemic, n (%)**Any
1252 (61.5)
745 (36.4)
598 (45.3)
440 (33.1)Grade 3
47 (2.3)
12 (0.6)
14 (1.1)
9 (0.7)**Fatigueb, n (%)**Any
891 (43.8)
451 (22.0)
392 (29.7)
277 (20.8)Grade 3
25 (1.2)
4 (0.2)
10 (0.8)
5 (0.4)**Headacheb, n (%)**Any
905 (44.4)
508 (24.8)
401 (30.4)
294 (22.1)Grade 3
18 (0.9)
5 (0.2)
5 (0.4)
4 (0.3)**Myalgiab, n (%)**Any
796 (39.1)
248 (12.1)
317 (24.0)
182 (13.7)Grade 3
29 (1.4)
1 (<0.1)
3 (0.2)
5 (0.4)**Nauseac, n (%)**Any
315 (15.5)
183 (8.9)
162 (12.3)
144 (10.8)Grade 3
3 (0.1)
3 (0.1)
3 (0.2)
3 (0.2)**Feverd, n (%)**Any
261 (12.8)
14 (0.7)
41 (3.1)
6 (0.5)Grade 3
7 (0.3)
0 (0.0)
1 (0.1)
0 (0.0)
a Solicited local and systemic adverse reactions collected for participants in a safety subset (N=6,736)
b Fatigue, Headache, Myalgia – Grade 3: use of prescription pain reliever or prevented daily activity
c Nausea – Grade 3: prevented daily activity
d Fever – Grade 3: ≥39.0 – ≤40.0°C or ≥102.1 – ≤104.0°F
Note: No grade 4 systemic reactions were reported.Analgesic/Antipyretics Use
Among vaccine recipients aged 18-59 years, 26.4% reported using antipyretic or analgesic medications, compared to 6.0% of placebo recipients. Among vaccine recipients aged ≥60 years, 9.8% reported using antipyretic or analgesic medications, compared to 5.1% of placebo recipients. The reason for medication use (e.g. fever, pain) was not ascertained.
Unsolicited Adverse Events
Overall, rates of reported unsolicited adverse events were similar in the vaccine and placebo groups (13.1% vs 12.0%). Reports of embolic and thrombotic events had a slight numerical imbalance with 0.06% of vaccine recipients and 0.05% of placebo recipients reporting such events. Risk factors for these events were present in the participants, however vaccine cannot be excluded as a contributing factor. Reports of tinnitus had a numerical imbalance with 6 events in vaccine recipients and no events in placebo recipients. Data are insufficient at this time to determine if there is a casual relationship between the vaccine and tinnitus. Angioedema demonstrated a numerical imbalance with events reported among 0.2% of vaccine recipients and 0.1% of placebo recipients. Of these, urticaria was reported in 8 vaccine recipients and 3 placebo recipients. Based on temporal and biologic plausibility, reports of urticaria are possibly related to vaccine.
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event, excluding those attributed to COVID-19, were 0.4% in the vaccine group and 0.4% in the placebo group. The most common serious adverse event occurring at higher rates in the vaccine group than the placebo group was appendicitis (6 cases in vaccine group vs. 5 cases in placebo group). Three serious adverse events occurring among vaccine recipients were considered by the U.S. Food and Drug Administration (FDA) as likely related to vaccine: the one report of hypersensitivity reaction to study vaccine, one report of pain at the injection site initially evaluated for brachial neuritis, and one report of systemic reactogenicity.
Data source: FDA briefing documentTop of Page
							
					
							Last Reviewed:  August 12, 2021						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue